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Abstract
Background: The IV use of human immunoglobulin (hIVIG) in dogs with primary
immune-mediated hemolytic anemia (IMHA) has been described previously, but
herein we describe the use of high-dose IgM-enriched hIVIG (Pentaglobin).
Hypothesis/Objectives: Dogs treated with high-dose Pentaglobin will experience
shorter time to remission and hospital discharge and have decreased transfusion
requirements compared to dogs receiving standard treatment alone.
Animals: Fourteen client-owned dogs diagnosed with primary IMHA at specialist
referral hospitals in the United Kingdom.
Methods: All prospectively enrolled dogs received prednisolone, dexamethasone or
both along with clopidogrel. Patients were randomized to receive Pentaglobin at 1 g/
kg on up to 2 occasions, or to serve as controls. No additional immunosuppressive
drugs were allowed within the first 7 days of treatment. Remission was defined as
stable PCV for 24 hours followed by an increase in PCV.
Results: Ten of 11 dogs from the treatment group and 2 of 3 dogs from the control
group achieved remission and survived until hospital discharge. Survival and time to
remission were not significantly different between groups. The volume of packed red
blood cells transfused, normalized for body weight, was not significantly different
between groups. Potential adverse reactions to Pentaglobin occurred in 2 dogs, but
their clinical signs may have been related to the underlying disease.
Conclusions and Clinical Importance: Treatment with high-dose Pentaglobin was
well tolerated by dogs with primary IMHA but no significant advantage was found in
this small study. Additional studies examining larger groups and subpopulations of
dogs with primary IMHA associated with a poorer prognosis are warranted.
Abbreviations: BUN, blood urea nitrogen; DAT, direct antiglobulin test; hIVIG, human IV immunoglobulin; IgA, immunoglobulin A; IgG, immunoglobulin G; IgM, Immunoglobulin M; IMHA,
immune-mediated hemolytic anemia; PCV, packed cell volume; PRBC, packed red blood cell; TED, thromboembolic disease.
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1 | INTRODUCTION
Human IV immunoglobulin (hIVIG) is created by purification of large vol-
umes of donor plasma.1 Depending on specific preparations, hIVIG typi-
cally contains immunoglobulin G (IgG) as its largest component with
smaller and variable amounts of immunoglobulin A (IgA), immunoglobulin
M (IgM), cluster of differentiation 4 (CD4), cluster of differentiation
8 (CD8), and human leukocyte antigen molecules.2 In the
United Kingdom, several hIVIG products are available, all of which con-
tain IgG as the primary immunoglobulin component (typically >90%)
along with a small amount of IgA and most have IgM as only a negligible
or trace fraction of the total immunoglobulin (<0.1 mg/mL). One product,
Pentaglobin, is unusual in this respect, being IgM-enriched and con-
taining 50 mg/mL human plasma protein, of which immunoglobulin is at
least 95%: 38 mg/mL IgG (76%), 6 mg/mL IgA (12%), and 6 mg/mL IgM
(12%). In contrast to IgG that is associated with longer term humoral
immunity, but provides more specific immunogenic functions to particu-
lar diseases, IgM is associated with polyreactivity, which allows B-
lymphocytes that can produce IgM to rapidly respond to many antigens.3
In human medicine, hIVIG is used primarily to manage patients with
immunodeficiencies, but it also is used to treat several inflammatory,
infectious, and autoimmune diseases.1,4-6 Low doses are administered at
regular intervals as replacement therapy for patients with immunodefi-
ciencies whereas high-dose regimens more frequently are used for
immunomodulatory treatment of patients with inflammatory or autoim-
mune diseases.7 Use of hIVIG in human medicine also has been reported
to prevent hemolysis associated with sickle cell disease, and for blood
transfusion in patients with lymphoma.1 Similarly, in veterinary medicine
hIVIG has been used for several diseases,2,8 including immune-mediated
hemolytic anemia (IMHA),9-13 immune-mediated thrombocytopenia,14-16
cutaneous drug reactions,17,18 and myasthenia gravis.19
The mechanism of action of hIVIG is complex and incompletely
understood. Elucidated mechanisms include binding to inhibitory and
activating fragment crystallizable (Fc) receptors, downregulation of cyto-
kine synthesis, eradication of autoantibodies, complement inhibition, and
mediation of Fas-Fas ligand interactions.1,2 Preparations of IgM-enriched
hIVIG had superior antiproliferative effects on T-lymphocytes compared
to standard hIVIG preparations in an in vitro mouse model.20 Likewise, in
an in vitro human model, Pentaglobin was found to have more potent
immunomodulatory capacity than standard hIVIG.21 There is ongoing
interest in its use in people with sepsis, with a meta-analysis indicating
that administration to adults with sepsis significantly decreased mortality
rates.22 A concept paper describes its use along with a monoclonal anti-
body (rituximab) in humans with mucocutaneous blistering diseases23
and the early use of IgM-enriched hIVIG (Pentaglobin) also appears to
decrease the risk of exchange transfusion, as well as the duration of
adjunctive phototherapy, in human patients with neonatal immune-
mediated hemolytic anemia.24
In dogs with IMHA, the destruction of erythrocytes is believed to
represent a type 2 hypersensitivity reaction secondary to the binding
of autoantibodies to cell membrane antigens.25 This binding leads to
destruction of the erythrocytes by the mononuclear phagocyte sys-
tem (extravascular hemolysis) or through complement fixation (intra-
vascular hemolysis).26 An in vitro study indicated that hIVIG binds to
canine lymphocytes and monocytes and inhibits Fc-mediated phago-
cytosis of autoantibody-opsonized erythrocytes.27 Hence, in theory,
hIVIG may assist in controlling hemolysis secondary to autoantibody
opsonization in acute IMHA. Primed erythrocyte-reactive lympho-
cytes also have been implicated in the pathogenesis of IMHA.28
Therefore, the aforementioned auxiliary effects of IgM-enriched
hIVIG, which may at least in part be a consequence of its interaction
with lymphocytes, also might be beneficial in dogs with IMHA.
Despite being a common hematological disorder in dogs,29 beyond
initial immunosuppressive treatment with glucocorticoids and the need
for thromboprophylaxis, limited evidence supports other treatments.30
This limited evidence, and associated high cost, has primarily restricted
hIVIG to salvage treatment in dogs refractory to standard immunosup-
pressive protocols, and cost saving considerations often lead to admin-
istration at lower doses. Several studies have examined the use of
hIVIG in dogs with IMHA, but no general agreement on its use has
been reached.9,10,13,31 These studies have utilized lower doses of hIVIG
than doses typically used in human patients where high-dose treatment
is preferred for immunomodulation.
Our objective was to investigate whether the use of high-dose,
IgM-enriched hIVIG would improve the initial response of dogs with
IMHA as compared to standard treatment (glucocorticoids and throm-
boprophylaxis). We hypothesized that high-dose IgM-enriched hIVIG
would be safe and effective, and that dogs treated with this product
along with standard treatment would experience a shorter time to
remission and hospital discharge and have decreased transfusion
requirements compared to dogs receiving standard treatment alone.
2 | METHODS
One of the study centers (Animal Health Trust) received a donation of
a large volume of IgM-enriched hIVIG that could not be utilized in the
human medical field because of regulatory issues. At the time of
receipt, only 5 months remained until product expiration. Ours was a
prospective, randomized, open-label, controlled study.
2.1 | Animals
Fourteen client-owned dogs, diagnosed with nonassociative (primary)
IMHA, were enrolled by participating referral hospitals, between
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March 2017 and July 2017. Cases were enrolled at the following UK-
based referral centers: Animal Health Trust, Dick White Referrals, The
Queen's Veterinary School Hospital (University of Cambridge), Davies
Veterinary Specialists and Pride Veterinary Centre. The study protocol
was approved by the Animal Health Trust's Clinical Research and Ethi-
cal Approval Committee (project number: 66-2016). An Animal Test
Certificate (Type S) was acquired for the experimental use of Pen-
taglobin from the Veterinary Medicines Directorate in the
United Kingdom. Written consent was obtained from owners of
included dogs. Included dogs underwent a minimum diagnostic inves-
tigation to establish a diagnosis of primary or nonassociative IMHA,
including: complete history, physical examination, hematology (includ-
ing reticulocyte count), serum biochemistry, thoracic and abdominal
imaging (thoracic radiography and abdominal ultrasound, or computed
tomography). Vector-borne disease testing was conducted at the dis-
cretion of the attending clinician, based on travel history and assessed
risk of exposure. A diagnosis of IMHA was based on the following
criteria: anemia (defined as PCV <35%) along with a positive saline
agglutination test, positive direct antiglobulin test (DAT) or moder-
ate to marked spherocytosis on a blood smear assessed by a board-
certified clinical pathologist. Dogs were excluded if investigations
showed evidence of an underlying disease that might lead to asso-
ciative (secondary) IMHA, the dog had received glucocorticoids for
>48 hours before study enrollment or if the dog had received
any other systemic immunosuppressant treatment before study
enrollment.
2.2 | Randomization
Enrolled dogs were randomly assigned to either the hIVIG treatment
group or control group. Because of limited time before the study drug
expiration and a desire to document the effects of the investigation
treatment, a case allocation of 2 : 1 (hIVIG treatment group: control
group) was utilized. Dogs were allocated by random selection of
sealed envelopes that dictated group assignment.
2.3 | Treatment
All enrolled dogs, in both the control and hIVIG treatment groups,
were treated with immunosuppressive dosages of glucocorticoids
(either prednisolone [1-3 mg/kg PO q24h] or dexamethasone
[0.15-0.3 mg/kg IV q24h]) and antiplatelet treatment (clopidogrel at a
loading dosages of 10 mg/kg PO on the first day followed by a dosage
of 2-4 mg/kg PO q24h). During hospitalization, daily monitoring of
PCV and total plasma protein concentration was performed as a mini-
mal monitoring requirement.
Dogs in the hIVIG treatment group were treated with IgM-
enriched hIVIG (Pentaglobin, Biotest Pharma, 63 303 Dreieich,
Germany) at a dosage of 1 g/kg IV at a fixed infusion rate of
1.7 mL/kg/hour using a syringe driver. During administration of hIVIG,
patients were monitored (heart rate, respiratory rate, temperature,
and blood pressure) and no other drugs or infusions were adminis-
tered concurrently.
The day of recruitment (also the day of diagnosis) was considered
study day 1 for the control and hIVIG treatment groups.
When a dog did not achieve stabilization of PCV within 24 hours
of the completion of the hIVIG infusion, the same dose was adminis-
tered on 1 additional occasion. However, if the patient received a
blood transfusion immediately after hIVIG infusion, then PCV stability
(for the purposes of justifying a second hIVIG infusion) was assessed
24 hours after the end of the blood transfusion.
The hIVIG preparation was stored at 4 to 6C and brought to
room temperature before administration.
For either treatment group, administration of other immunosup-
pressive drugs was not allowed within the first 7 days of treatment.
The use of additional supportive treatments (eg, IV fluids, blood trans-
fusions, analgesia, gastroprotectants, or antibiotics), however, was
allowed at the discretion of attending clinicians. Remission was
defined, for the purpose of the study, as stabilization of PCV for
24 hours followed by subsequent increases and lack of requirement
for additional blood transfusions. After 7 days, if remission was not
achieved, other immunosuppressants could be utilized as deemed
appropriate by the attending clinician.
2.4 | Data collection
Data recorded during the study period included time to remission,
number, and volume of packed red blood cell (PRBC) transfusions,
duration of hospitalization, patient survival to discharge, 90-day
follow-up and information on any suspected adverse reactions, and
cause of death (if applicable).
2.5 | Statistical analysis
Data were collated and summarized using Microsoft Excel 2011. A
commercial statistics package (MedCalc 19.2.0, MedCalc Software)
was used for statistical analyses. Variables between the control group
and hIVIG treatment group were compared using nonparametric tests:
Fisher's exact test for datasets with categorical variables and Mann-
Whitney U test for datasets with continuous variables. A P value of
<.05 was considered significant.
3 | RESULTS
Fourteen dogs with nonassociative IMHA were enrolled into the
study. Three were assigned to the control group and 11 to the hIVIG
treatment group. No enrolled dogs were excluded from the study. No
significant difference was found between the control group and hIVIG
treatment group in weight, age, sex, or PCV at presentation (Table 1).
Of previously proposed prognostic indicators (increased blood urea
nitrogen [BUN] and total bilirubin concentration, decreased platelet
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count, presence of petechiae and increased band neutrophils),32,33
none were statistically different between the 2 groups (Table 1). The
presence of hemoglobinemia and hemoglobinuria, as markers of
intravascular hemolysis, also was not statistically different between
groups (Table 1).
Infectious disease testing was performed in 10/11 dogs in the
hIVIG treatment group and in 2/3 dogs in the control group. Most
dogs had serology performed for Borrelia burgdorferi, Ehrlichia canis,
Ehrlichia ewingii, Anaplasma phagocytophilum, Anaplasma platys, and
Dirofilaria immitis (SNAP 4Dx Plus Test, IDEXX Laboratories Inc,
Westbrook, Maine; 2/3 dogs in the control group; 8/11 dogs in the
hIVIG treatment group). Some dogs also underwent serological testing
for Angiostrongylus vasorum (Angio Detect, IDEXX Laboratories Inc,
Westbrook, Maine; 0/3 dogs in the control group and 2/11 dogs in
the hIVIG treatment group). Other infectious disease screening
included PCR testing for Babesia spp. (0/3 dogs in the control group
and 6/11 dogs in the hIVIG treatment group), hemotropic Mycoplasma
spp. (0/3 dogs in the control group and 2/11 dogs in the hIVIG treat-
ment group), and Anaplasma spp. and Ehrlichia spp. (0/3 dogs in the
control group and 2/11 dogs in the hIVIG treatment group). All infec-
tious disease screening performed was negative.
Figure 1 summarizes the outcomes of the 14 dogs enrolled in the
study. Between the control and hIVIG treatment groups, no significant
difference was found as to whether remission or hospital discharge
was achieved, nor in the duration of time to remission or hospital dis-
charge (Table 2).
All dogs in the control group (3/3) and 8 of 11 dogs in the hIVIG
treatment group received PRBC transfusions. No significant differ-
ence was found in the amount of blood product received between the
2 groups (Table 2). In all dogs that developed stable PCV for 24 hours,
PCV subsequently increased and the dogs were discharged without
need for additional blood transfusions.
In the control group, 2 of 3 dogs achieved remission and survived
to hospital discharge (Table 2). The dog that did not achieve remission
was euthanized in the hospital on study day 4. Euthanasia was as a
result of a decreasing PCV, with additional treatment declined by the
TABLE 1 Comparison of variables, at the time of diagnosis, between dogs within the control group and hIVIG treatment group
Parameter hIVIG treatment group Control group P-value
Weight (kg) 15.2 (9.7-22.0) 17.2 (12.6-38.0) .44
Age 7.0 (0.6-13.0) 4.3 (2.8-5) .31
Sex 5 male (3 neutered, 2 entire)/6 female (5
neutered, 1 entire)
1 male (neutered)/2 female (both
neutered)
1
PCV (%) at presentation 16 (9-24) 17 (10-26) .7
Positive DAT 2/5 Not performed in any dog –
Positive saline agglutination test 8/11 2/2 –
Spherocytosis 10/11 3/3 –
Presence of petechiae 0/11 0/11 1
Platelet count (109/L) 207 (11-734) 512 (236-571) .13
Band neutrophils (109/L) 1.00 (0.21-1.90) 0.10 (0.00-6.68) .46
Total bilirubin (mg/dL) at presentation 0.9 (0.1-26.4) 0.8 (0.3-0.9) .44
BUN (mg/dL) at presentation 18.2 (11.8-45.7) 13.2 (7.0-14.3) .05
Presence of hemoglobinemia (visual
assessment of plasma)
6/11 2/3 1
Presence of hemoglobinuria 0/3 1/2 .4
Note: Median and (range) displayed; or, number of affected or positive dogs/number of dogs or tests performed.





Ten dogs achieved 
remission and 
survived to discharge





Two dogs achieved 
remission and 
survived to discharge
One dog euthanized 
(remission not 
achieved)
F IGURE 1 Flow diagram summarizing the outcomes of dogs
enrolled in the current study. TED, thromboembolic disease
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owners. The 2 dogs in the control group that survived to hospital dis-
charge were still alive, receiving ongoing medical management, and in
remission on study day 90.
In the hIVIG treatment group, 10 of 11 patients achieved remission
and survived to hospital discharge (Table 2). The dog that did not achieve
remission deteriorated and died on study day 4. The cause of death was
suspected to be sepsis and thromboembolic disease (TED) but these
diagnoses were not confirmed and a necropsy was not performed. Of
the 10 dogs that achieved remission and hospital discharge, 7 were alive
and still in remission with ongoing medical treatment at study day 90. Of
the remaining 3 dogs, 2 were lost to follow-up, but at the time of last
follow-up (study day 60 for 1 dog and 49 for the other) the dogs were
reported to be in remission and still receiving medical treatment. The
remaining dog was euthanized on study day 18 at the owners' request at
the primary veterinary practice. Based upon assessment of the available
medical record at that time, euthanasia was requested despite continued
remission with medical treatment, and because of potential steroid-
related adverse effects. Enlarged submandibular lymph nodes had been
identified on examination at this time, but cytology findings were consis-
tent with reactive lymphoid hyperplasia.
In the hIVIG treatment group, because of various factors, includ-
ing time of presentation (ie, presentation out-of-hours as an emer-
gency vs routine appointment) and the concurrent requirement for
blood transfusion, patients in the hIVIG group received their first infu-
sion on a median of study day 2 (range, 1-2). Most dogs (7/11)
received only 1 infusion of IgM-enriched hIVIG; 4 dogs, that had a
decrease in PCV within 24 hours after the first, received 2 hIVIG infu-
sions. These included the 2 dogs that experienced potential adverse
reactions to the infusion of IgM-enriched hIVIG. One of these dogs
was the aforementioned patient that died on study day 4 because of
suspected sepsis and TED. The other dog experienced transient
tachypnea the day after a second infusion of hIVIG. This dog had also
received a PRBC transfusion in the 24 hours before the first hIVIG
infusion. Tachypnea resolved during hospitalization without further
investigation or treatment. This dog achieved remission on study day
5 and was alive on study day 90. The remaining 2 dogs that received
2 hIVIG infusions also received additional second-line immunosup-
pressant agents, and were both alive on study day 90. For 1 of these
dogs, mycophenolate mofetil was prescribed on study day 11 before
remission was achieved on day 17. This dog survived to hospital dis-
charge, but was lost to follow-up on study day 49, at which time
remission was sustained on a decreased dose of prednisolone and
concurrent ongoing management with mycophenolate mofetil. The
second dog was prescribed azathioprine on study day 26 because of
development of thrombocytopenia despite continued remission of the
IMHA. This dog was a Cavalier King Charles Spaniel and had some
macroplatelets observed on blood smear evaluation but, before the
consistent findings of thrombocytopenia, normal platelet counts had
been documented and, after the addition of azathioprine, thrombocy-
topenia resolved, leading to a presumptive diagnosis of immune-
mediated thrombocytopenia. This patient achieved remission from
IMHA (on study day 6) and hospital discharge, and was alive and in
remission at study day 90.
4 | DISCUSSION
Our study aimed to evaluate the use of high-dose IgM-enriched hIVIG
in dogs with IMHA in a prospective, randomized, controlled manner.
In this cohort, we found no significant difference between the treat-
ment and control groups in terms of measured outcome variables.
Potential adverse effects to hIVIG were reported in 2 of the
11 dogs that received the treatment. One dog died as a result of these
potential complications (sepsis and TED) whereas the other experi-
enced self-resolving tachypnea (suspected TED). However, definitive
diagnosis of TED was not obtained in either case, and therefore it is
difficult to be certain of this diagnosis. Furthermore, dogs with IMHA
are known to already be at increased risk of TED,34 and the timing of
TABLE 2 Comparison of treatment and outcome variables between dogs within the control group and hIVIG treatment group
Parameter hIVIG treatment group Control group P-value
Initial glucocorticoid treatment
and dose
Dexamethasone IV: 5/11; 0.3 mg/kg/day
(0.23-0.3 mg/kg/day)
Prednisolone PO: 6/11; 2 mg/kg/day
(1.6-2 mg/kg/day)
















Day of remission 3 (2-17) 6 (2-10) 1
Day of discharge 6 (4-28) 8.5 (4-13) .91
Day-90 status 7 alive/2 dead (2 lost to follow-up) 2 alive/1 dead 1
Note: Number of treated dogs/total number of dogs; median and (range) displayed; or, number of dogs alive/number of dogs dead.
Abbreviation: PRBC, packed red blood cells.
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events in both of these patients makes the relationship to treatment
questionable. Adverse effects to hIVIG are reported to occur in 32%
of people but are usually mild (fever being most common) and often
can be managed by decreasing the infusion rate.35 As in our study,
adverse effects reported in other veterinary studies appear infrequent
and include swelling at catheter sites, volume overload, erythema, and
anaphylaxis.13,19 A hypercoagulable and a proinflammatory state,
without clinical signs, also has reported in a small group of experimen-
tal dogs that received a single infusion of hIVIG.36 This observation,
along with the known increased risk of TED in dogs with IMHA, sug-
gests that thromboprophylaxis might be particularly crucial in dogs
with IMHA that receive hIVIG. In our study, clopidogrel was used on
the basis of available literature, affordability, and ease of administra-
tion.37 However, the American College of Veterinary Internal Medi-
cine (ACVIM) consensus statement on the treatment of IMHA,
published after the completion of our study, recommends the use of
anticoagulant drugs in preference to antiplatelet treatment, but the
strength of this recommendation is weak30 and anticoagulants typi-
cally are more expensive, require additional monitoring and are less
practical to administer over the long term, often requiring owners to
give frequent injections. If antiplatelet drugs are used, clopidogrel is
suggested over or along with aspirin, based on the available litera-
ture.30,37-39 No adverse effects were observed with the use of
clopidogrel (including the loading dose) in our study.
Of interest in our study was the use of higher than previously uti-
lized doses of hIVIG in dogs. In previous studies,9,13 smaller doses
were used than in our study. One of these studies was a blinded ran-
domized clinical trial that recruited 28 nonassociative IMHA cases in
dogs (14 in the hIVIG treatment group and 14 in the placebo group).13
The dogs that received hIVIG had 0.5 g/kg administered over 6 hours
on 3 consecutive days (1.5 g/kg total dose). The other study was ret-
rospective and included 22 dogs (9 of which were treated with hIVIG)
over a 6-year period from a single institution.9 The dogs that had
hIVIG administered received a median dose of 0.35 g/kg (range,
0.19-0.68 g/kg). In both studies, no significant benefit was observed
from treatment with hIVIG. In human medicine, doses of hIVIG are
variable depending on the disease treated but higher doses, most fre-
quently 2 g/kg/month, typically are recommended for the treatment
of autoimmune diseases.1 Therefore, our study allowed for the deliv-
ery of 1 g/kg of IgM-enriched hIVIG with a repeated dose if disease
remission was not achieved within 24 hours (total dose of 2 g/kg).
Four of the 11 dogs that received hIVIG in our study received 2 hIVIG
transfusions and, therefore, the maximal dose. Two of these dogs
experienced potential adverse reactions, but these effects may not
have been related to hIVIG administration.
An additional point of interest when examining both our study
and the previous study13 is the overall good survival rates both for
dogs treated with hIVIG and the placebo or control groups. This find-
ing is in contrast to the high mortality rates of up to 70%40 reported
for dogs with IMHA in older veterinary literature. A more recent publi-
cation, based on data from a British multicenter online case registry,
reported higher survival rates of dogs with primary IMHA, describing
25.7% mortality at discharge, and 30-day mortality of 32.6%.32
However, these mortality rates still appear higher than those seen in
our study where mortality was 14.3% at discharge and 21.4% at
30-days. Although our study represents a relatively small data set, this
finding could suggest that dogs treated with a strict and consistent
treatment and monitoring regimen, including thromboprophylaxis,
might experience better outcomes. Additional credence might be
added to this idea with future longitudinal studies following the recent
publication of ACVIM consensus statements on the diagnosis and
management of IMHA, which aim to rationalize and standardize treat-
ment approaches.30,41 The latter of these consensus statements con-
cludes that hIVIG should be considered as a salvage treatment for
dogs unresponsive to 2 immunosuppressive drugs, and hIVIG is not
currently recommended for routine treatment.30
Our study was limited by small sample size and, therefore,
restricted ability to perform statistical analysis and detect statistical
differences in patient outcome. Unfortunately, this small sample size
was unavoidable as a result of factors surrounding use of the IgM-
enriched hIVIG preparation. The product (Pentaglobin) was donated
to 1 of the institutions (Animal Health Trust) but with a limited shelf-
life (an expiration date of July 2017) and therefore all cases were
enrolled between March 2017 and July 2017. Several centers were
recruited to maximize enrollment of cases within the available time.
To ensure enrollment of an adequate number of cases to the hIVIG
treatment group, a randomization allocation of 2 : 1 was used for the
hIVIG treatment and control groups. However, this approach ulti-
mately led to the recruitment of a minimal number of control dogs,
which impacted the ability to detect significant differences between
the control and hIVIG treatment groups. Continued enrollment of
control cases was considered but not performed because of the possi-
ble introduction of selection bias. Post hoc power calculations indicate
that the cases collected to that point only had a power of 25% to
detect a difference in survival between treatment groups. Moreover,
if the same survival rates could be extrapolated to a larger data set,
several hundred control cases would need to be recruited to identify a
significant survival benefit to the treatment with only 11 cases in that
group, making it a futile endeavor. If there is a survival benefit in using
hIVIG at presentation in dogs with IMHA, it is likely to be small and
studies to identify it are quite possibly cost prohibitive. Future studies
should be more targeted, evaluating only those cases for which the
prognosis is thought to be poor such that any benefit is more readily
identifiable.
The inclusion criteria for our study were less stringent than the
diagnostic algorithm proposed by the recent ACVIM consensus state-
ment for the diagnosis of IMHA in dogs and cats.41 However, retro-
spectively, all dogs in our study met the consensus statements'
criteria (≥2 signs of immune-mediated destruction and ≥1 sign of
hemolysis) to be considered diagnostic for IMHA. Two dogs did not
undergo infectious disease screening. Although some infectious
organisms may cause IMHA,41 these are uncommon in the
United Kingdom, where the study was performed, and generally are
not seen in dogs with an absence of travel history. Compared with
other countries, where infectious disease screening is imperative for
achieving a diagnosis of nonassociative IMHA, the decision to
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undertake infectious disease testing, and the breadth of that testing,
was decided on a case-by-case basis dictated by clinical history and
index of suspicion.
Markers of intravascular hemolysis, hemoglobinemia, and hemo-
globinuria were assessed where the information was available. How-
ever, measurement of cell-free hemoglobin was unavailable and
assessment of hemoglobinemia was based on visual inspection of
plasma, which could have been spurious secondary to sample collection
(eg, traumatic venipuncture), handling or storage.42-44 Urinalysis and
assessment of hemoglobinuria was only available for a small number of
dogs. Therefore, it is difficult to draw conclusions about the number of
dogs in our study with intravascular hemolysis. Future studies are
warranted to assess if hIVIG treatment, and in particular IgM-enriched
hIVIG, might preferentially benefit dogs with intravascular hemolysis.
Our study was nonblinded, which could have created bias.
Blinding and the use of a placebo infusion was considered, but given
that fluid overload was a possible risk considered for these IMHA
patients, because of the combination of anemia, blood transfusions
and potential IV fluid therapy, the addition of an additional nonessen-
tial IV transfusion (ie, placebo drug) was not considered safe, ethical,
or legal in the United Kingdom. Additionally, remission was considered
confirmed by identification of a stable PCV, an objective variable that
should be less prone to bias than a subjective outcome.
5 | CONCLUSION
This multicenter prospective study suggested that high-dose IgM-
enriched hIVIG, in addition to glucocorticoids, is well tolerated by
patients but no significant benefits were found compared to glucocor-
ticoids alone in this small cohort. Additional studies utilizing larger
groups of dogs with IMHA using a blinded study design and a
placebo-controlled group are warranted, in addition to studies exam-
ining subpopulations of dogs with IMHA associated with a poorer
prognosis to determine if hIVIG treatments would benefit such cases.
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